Scarica l'app Stockscreener
692.83
0.61%
-4.22
Dopo l'orario di chiusura:
692.83
Argen X Se Adr Borsa (ARGX) Ultime notizie
argenx SE (HAM:1AEA) Stock Price, Trades & News - GuruFocus
Argenx SE Stock Faces Pressure Amid Pipeline Setbacks and Market Volatility in Biotech Sector - AD HOC NEWS
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Motley Fool
Form 6K argenx NV ADR For: 20 March By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 20 March - Investing.com
argenx announces Annual General Meeting of Shareholders on May 6, 2026 - ChartMill
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Argenx SE stock faces pressure as Iron Triangle Partners trims position amid biotech sector watchlis - AD HOC NEWS
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
TD Cowen reiterates argenx stock Buy rating on growth outlook By Investing.com - Investing.com India
TD Cowen reiterates argenx stock Buy rating on growth outlook - Investing.com
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’ - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal - Investing.com South Africa
Forecasting The Future: 16 Analyst Projections For argenx - Sahm
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached - Finviz
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock - Finviz
Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - marketscreener.com
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - ChartMill
Empowering Investor Success - Morningstar
Argenx Benefits From Strong Growth for Vyvgart; Pipeline Continues to Make Progress - Morningstar
Oppenheimer raises argenx stock price target to $1,060 on sales growth - Investing.com
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
Citizens raises argenx stock price target on ocular MG results - Investing.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
argenx Q4 2025 slides: first profitable year, 90% revenue surge By Investing.com - Investing.com Australia
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
Earnings call transcript: Argenx Q4 2025 sees strong earnings beat, stock dips - Investing.com
BofA raises argenx stock price target to $1,013 on trial success - Investing.com
Stifel cuts argenx stock price target to $1,227 on valuation - Investing.com India
argenx Q4 2025 slides: first profitable year, 90% revenue surge - Investing.com South Africa
ARGENX : Gets a Buy rating from Goldman Sachs - marketscreener.com
ARGENX : Barclays reiterates its Buy rating - marketscreener.com
Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial - marketscreener.com
ARGENX : Receives a Buy rating from Bernstein - marketscreener.com
Argenx reports $1.3 billion in Q4 global product net sales - marketscreener.com
Argenx: Positive topline results from phase 3 adapt oculus trial of Vyvgart in oMG - marketscreener.com
argenx ADR earnings beat by $2.07, revenue topped estimates - Investing.com
Argenx Says Phase 3 Study of Ocular Myasthenia Gravis Therapy Met Main Goal - marketscreener.com
Argenx SE FY25 swings to profit as Vyvgart sales double - Investing.com
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Argenx Reports Higher FY25 Attributable Profit, Operating Income - marketscreener.com
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Insights into argenx's Upcoming Earnings - Sahm
Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART - Insider Monkey
argenx to Present at TD Cowen 46th Annual Healthcare Conference - ChartMill
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 - Sahm
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Finviz
0.16%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):